Navan Technologies Inc.

Medtech · Private

A nanomaterial-based (nanostraw) device for nondestructive delivery of genes and reprogramming agents into primary immune cells with high transfection efficiency and low toxicity.

Grants
$1.1M
1 award
Sector median: 1
Raised
—
No Form D on record
Contracts
—
No federal contracts on record
Patents
3
0 granted · 3 pending
Sector median: 2

Capital Timeline

Federal above the line · equity below · node area scaled to amount
Capital and federal award history
DateEventSourceAmount
Federal grantNational Science Foundation · Phase II · STTR Phase II: Nanostraw-mediated Immune Cell Reprogramming$1,149,998
Federal grant · SBIR/STTR

Peer position

Medtech · 4531 companies · ranked on federal contract value
Medtech companies ranked by federal contract value
#CompanyContractsDisclosed equity
1970ALSUS MEDICAL, INC.——
1971CELEFLUX LLC——
1972Vizgen—$295M
1973Navan Technologies Inc.——
1974VISIONAIRE PRODUCTS, INC——
1975REFER2INPUT, LLC——
1976CADUCEUS WIRELESS, INC.——

Ranked on federal contract value rather than capital raised. The equity column is the comparison worth making — companies at the same procurement position often sit at very different points in their funding history.

Patents

USPTO · 0 granted of 3
  • Methods And Apparatuses For Biomolecule Delivery To Primary Human Hematopoietic Stem Cells Using Nanostrawsapplication
  • Methods And Apparatuses For Biomolecule Delivery To Primary Human Hematopoietic Stem Cells Using Nanostrawsapplication
  • Methods And Apparatuses For Biomolecule Delivery To Primary Human Hematopoietic Stem Cells Using Nanostrawsapplication

Regulatory activity · Medtech

Sector-level, not company-level

Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.